Envisagenics, Inc. announced that it has raised $25 million in a round of funding on June 4, 2024. The transaction included participation from returning investors New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, and new investor Bristol-Myers Squibb Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.86 USD | -0.27% | -4.46% | -19.90% |
03:41pm | Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5 | MT |
01:26pm | Bristol Myers: Board declares dividend | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.90% | 8.31TCr | |
+51.86% | 80TCr | |
+40.51% | 63TCr | |
-6.68% | 35TCr | |
+17.08% | 32TCr | |
+10.46% | 30TCr | |
+16.87% | 24TCr | |
+1.02% | 22TCr | |
+5.68% | 16TCr | |
-5.49% | 15TCr |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company